Preferred Label : Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707;
NCIt synonyms : ACTR707 Cells; ACTR707 T-cells; ACTR707;
NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified, using
proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, to express a chimeric
protein containing, at least, the extracellular Fc receptor domain of CD16, normally
found on certain immune cells, such as natural killer (NK) cells, coupled to the co-stimulatory
signaling domain of CD28, with potential immunostimulating and antineoplastic activities.
Upon reintroduction into the patient with co-administration of a cancer-specific antibody,
the co-administered antibody targets and binds to the tumor-associated antigen (TAA)
expressed on the tumor cell. In turn, the autologous ACTR-CD16-CD28-expressing T-lymphocytes
ACTR707 bind to the antibody, become activated and induce the destruction of the tumor
cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines
that trigger an immune response and recruit other immune-mediated killer cells to
kill the tumor cells; c) targeting and killing adjacent tumor cells that are not bound
to the antibody; d) inducing T-cell proliferation and thereby further enhancing the
T-cell mediated tumor cell attack. Compared to other T-cell products, ACTR-based products
do not target a specific TAA and can potentially be used in a variety of tumors because
targeting is based on the specificity of the co-administered antibody.;
NCI Metathesaurus CUI : CL537915;
Origin ID : C139730;
UMLS CUI : C4682464;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
